FDA
-
-
-
-
-
-
-
Wolfe Research Downgrades Corcept Therapeutics (CORT) to Underperform
-
-
-
-
-
-
-
Corcept Presents New Data at ASCO 2026: Lifyorliâ„¢ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
-
-
-
-
-
-
-
Corcept to present ROSELLA trial data at ASCO 2026
-
-
-
-
-
-
-
FDA approves Corcept's Lifyorli for platinum-resistant ovarian cancer
-
-
-
-
-
-
-
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
-
-
-
-
-
-
-
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
-
-
-
-
-
-
-
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT
-
335,399 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


